期刊
CELLS
卷 10, 期 1, 页码 -出版社
MDPI
DOI: 10.3390/cells10010019
关键词
Siglec-8; mast cells; eosinophils; monoclonal antibodies; glycan ligands; AK002; lirentelimab
类别
资金
- National Institute of Allergy and Infectious Diseases [U19AI136443, U19AI070535, 107905120]
Siglec-8 is a cell surface receptor with inhibitory activities on immune cells, being selectively expressed on human mast cells and eosinophils. AK002, an antibody targeting Siglec-8, has shown potential in clinical development for diseases involving mast cells and eosinophils.
Siglecs (sialic acid-binding immunoglobulin-like lectins) are single-pass cell surface receptors that have inhibitory activities on immune cells. Among these, Siglec-8 is a CD33-related family member selectively expressed on human mast cells and eosinophils, and at low levels on basophils. These cells can participate in inflammatory responses by releasing mediators that attract or activate other cells, contributing to the pathogenesis of allergic and non-allergic diseases. Since its discovery in 2000, initial in vitro studies have found that the engagement of Siglec-8 with a monoclonal antibody or with selective polyvalent sialoglycan ligands induced the cell death of eosinophils and inhibited mast cell degranulation. Anti-Siglec-8 antibody administration in vivo to humanized and transgenic mice selectively expressing Siglec-8 on mouse eosinophils and mast cells confirmed the in vitro findings, and identified additional anti-inflammatory effects. AK002 (lirentelimab) is a humanized non-fucosylated IgG1 antibody against Siglec-8 in clinical development for mast cell- and eosinophil-mediated diseases. AK002 administration has safely demonstrated the inhibition of mast cell activity and the depletion of eosinophils in several phase 1 and phase 2 trials. This article reviews the discovery and functions of Siglec-8, and strategies for its therapeutic targeting for the treatment of eosinophil- and mast cell-associated diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据